Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used diabetes and obesity medications but have been associated with gastrointestinal (GI) adverse events. However, real-world evidence on comparative GI adverse reaction profiles is limited. Objectives: This study aimed to evaluate GI adverse events among GLP-1 RA users and compare semaglutide, dulaglutide, liraglutide, and exenatide safety regarding the GI adverse reaction profile. Methods: This retrospective cross-sectional analysis utilized real-world data on 10,328 adults with diabetes/obesity in the National Institutes of Health All of Us cohort. New GLP-1 RA users were identified, and GI adverse events were examined. Logistic regression determined factors associated with GI adverse events. Results: The mean age of the study population was 61.4 ± 12.6 years, 65.7% were female, 51.3% were White, and they had a high comorbidity burden. Abdominal pain (57.6%) was the most common GI adverse event, followed by constipation (30.4%), diarrhea (32.7%), nausea and vomiting (23.4%), GI bleeding (15.9%), gastroparesis (5.1%), and pancreatitis (3.4%). Dulaglutide and liraglutide had higher rates of abdominal pain, constipation, diarrhea, and nausea and vomiting than semaglutide and exenatide. Liraglutide and exenatide had the highest pancreatitis (4.0% and 3.8%, respectively). Compared to semaglutide, dulaglutide and liraglutide had higher odds of abdominal pain, and nausea and vomiting. They also had higher odds of gastroparesis than semaglutide. No significant differences existed in GI bleeding or pancreatitis risks between the GLP-1 RAs. Conclusions: In this real-world cohort, GI adverse events were common with GLP-1 RAs. Differences in GI safety profiles existed between agents, with exenatide appearing safer than other GLP-1 RAs, except for gastroparesis. These findings can inform GLP-1 RA selection considering GI risk factors. Further studies are needed to evaluate the causal relationship and GLP-1 RA safety with concomitant medication use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The “All of Us” Research Program
The All of Us Research Program Investigators (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1809937 · Cited by 2,440
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 4×
“GLP-1 RAs comprise several compounds with varying pharmacokinetic properties, duration of action, and clinical effectiveness [1,2].”
InfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 2×
“GLP-1 RAs comprise several compounds with varying pharmacokinetic properties, duration of action, and clinical effectiveness [1,2].”
The “All of Us” Research Program
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1912496 · Cited by 843
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 2×
“Multivariable logistic regression was used to determine factors associated with gastrointestinal adverse events, adjusting for sociodemographics, comorbidities, and medication type.”
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“Multivariable logistic regression was used to determine factors associated with gastrointestinal adverse events, adjusting for sociodemographics, comorbidities, and medication type.”
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471 · cited 1×
“Recent research has linked the use of GLP-1 RAs for weight loss to an increased risk of pancreatitis, gastroparesis, and bowel obstruction [14].”
The All of Us Research Program: Data quality, utility, and diversity
Ramirez, A. H., Sulieman, L., Schlueter, D. J., Halvorson, A., Qian, J., Ratsimbazafy, F., Loperena, R., Mayo, K., Basford, M., Deflaux, N., et al. (2022) · Patterns · doi:10.1016/j.patter.2022.100570 · Cited by 352 · cited 2×
“This study followed the Strengthening the Reports of Observational Studies in Epidemiology reporting guideline.”
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297 · cited 1×
“This occurs through directly stimulating POMC/CART neurons and indirectly inhibiting neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which can lead to reduced energy intake [3].”
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280 · cited 1×
“They are also used as an adjunct for weight loss in people without diabetes [7].”
Cited by
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00331-y · Cited by 55
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
Osei, S. P., Akomaning, E., Florut, T. F., Sodhi, M., Lacy, B. E., Aldhaleei, W. A., & Bhagavathula, A. S. (2024) · Diagnostics · doi:10.3390/diagnostics14242829 · Cited by 38
Self-citationRaubenheimer, J., Myburgh, P. H., & Bhagavathula, A. S. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00095-w · Cited by 41
Self-citationKunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
Ramírez-Mejía, M. M., Ponciano‐Rodríguez, G., Eslam, M., & Méndez-Sánchez, N. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251406456 · Cited by 44
McCall, K. L., Mastro, K. A., Casey, R. T., Samana, T. N., Sulicz, E. K., Tso, S. Y., Yalanzhi, E. R., & Piper, B. J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2499670 · Cited by 31
“The prominence of GI AEs in both groups was expected, aligning with the known side effect profile of GLP-1 RAs [17].”
Safwan, M., Bourgleh, M. S., Alotaibi, S. A., Alotaibi, E. A., Al-Ruqi, A., & Raeya, F. E. (2025) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2025.129 · Cited by 77
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
“Notably, it was associated with chronic kidney disease (CKD) but showed no significant differences across various GLP-1RAs such as semaglutide, dulaglutide and liraglutide (Aldhaleei et al., 2024).”
Abdulhameed, N., Babin, A., Hansen, K. M., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01537-1 · Cited by 27
“This route of administration has the added advantage of limiting adverse gastrointestinal effects (nausea, diarrhea, and vomiting) associated with subcutaneous IRA therapy [67–69] and are of particular concern in an already vulnerable AD population.”
Bayoumy, A. B., Clarke, L. M., Deepak, P., Desai, A., Sehgal, P., Gorelik, Y., Bar‐Yoseph, H., Villumsen, M., Mulder, C. J. J., Stenvers, D. J., et al. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf181 · Cited by 26
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
“A potential risk of pancreatitis was also seen, but the incidence was very low [70].”
Al‐Soleiti, M., Leung, J. G., Mubaydeen, T., Markota, M., Abulseoud, O. A., Singh, B., & Sola, C. L. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002090 · Cited by 24
The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
Echeverry-Guerrero, S., González-Vélez, S., Arévalo-Lara, A.-S., Calvache-Orozco, J.-C., Villarroel-Hagemann, S. K., Rojas-Rodríguez, L. C., Pérez-Acosta, A. M., & Calderón‐Ospina, C. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3040025 · Cited by 20
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 21
Myths and Facts Regarding Low-Carbohydrate Diets
Teicholz, N., Croft, S. M., Cuaranta, I., Cucuzzella, M. T., Glandt, M., Hafez, D., Jerome-Zapadka, K., Kalayjian, T., Murphy, K. C., Nelson, M., et al. (2025) · Nutrients · doi:10.3390/nu17061047 · Cited by 17
“While GLP-1 agonists may be helpful, these are associated with serious side effects, including gastroparesis and pancreatitis [44], and in some studies have been found to have high discontinuation rates (>50”
Sadraei, S., Aarabi, A., Firouzabadi, S. R., Alinejadfard, M., Mohammadi, I., & Jolfayi, A. G. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05278-3 · Cited by 13
“Finally, semaglutide has been associated with a lower incidence of gastrointestinal adverse events compared to other GLP-1 RAs, such as dulaglutide and liraglutide [46, 47].”
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 14
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
McIntyre, R. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241087 · Cited by 12
Aneke-Nash, C. S., Hung, K. S., Wall‐Wieler, E., Zheng, F., & Sharaiha, R. Z. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2024-001704 · Cited by 9
“12–14 Conversely, sleeve gastrectomy (SG) has been shown to accelerate gastric emptying.”
Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies
Liu, J., Huang, X. J., Wang, M., & Yang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i8.1663 · Cited by 9
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes
Sarwal, A., Singh, R., Wei, G., Shen, J., Nevers, M. R., Hartsell, S. E., Derington, C. G., Takyi, A., Chakravartula, A. R., Katkam, N., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16642 · Cited by 8
“8 In addition, as mentioned above, a recent ACNU design study reported a higher risk of gastroparesis compared to bupropion-naltrexone for weight loss.”
Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
Patel, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176060 · Cited by 7
“In a recent retrospective review, GI side effects were more common in women than in men and more prevalent in patients with chronic kidney disease (CKD) and heart failure [21].”
InfluentialIlie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Cacciapuoti, F., Mauro, C., Capone, V., Sasso, A., Tarquinio, L. G., & Cacciapuoti, F. (2024) · Heart and Mind · doi:10.4103/hm.hm-d-24-00050 · Cited by 8
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
“These include amylin analogue, GIP receptor agonist and glucagon receptor agonist.”
Unmasking Aspiration Risks: A Propensity‐Matched Odyssey of GLP‐1 Receptor Agonists and Colonoscopy
Chhabra, P., Bhandari, R., & Singh, R. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70071 · Cited by 7
Calvarysky, B., Gal, Y., Kushnir, S., Turjeman, ., Shochat, T., Dotan, I., & Diker‐Cohen, T. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70116 · Cited by 5
Spanakis, M., Fournaraki, A., Nimee, F., Kontogiorgis, C. A., & Symvoulakis, E. K. (2026) · Pharmaceuticals · doi:10.3390/ph19020271 · Cited by 7
Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity
Jo, S., Gu, J., Chen, J., Xu, G., & Shalev, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16223 · Cited by 5
“3,4 This underlines the remaining need for novel oral medications with different, milder effects to improve obesity-associated impairment in glucose homeostasis long-term, especially given the ever growing number of people affected by diabetes and prediabetes.”
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
Lawati, A. A., Alhabsi, A. N., Rahul, R., Savino, M.-L., Alwahaibi, H., Das, S., & Lawati, H. A. (2025) · Diseases · doi:10.3390/diseases13050129 · Cited by 5
“As such, Liraglutide should be used with caution in patients at higher risk for pancreatitis (e.g., alcohol abuse, history of pancreatitis, cholelithiasis) [38,39].”
The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025) · Nutrients · doi:10.3390/nu17193038 · Cited by 4
“Conversely, a recent retrospective cross-sectional analysis utilizing real-world data from 10.328 adults with DM or obesity in the National Institutes of Health All of US cohort identified that 3.144 cases of constipation among new users of GLP-1 RAs who reported GI AEs [72].”
InfluentialNew therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review
Doroba, O., Czupryniak, L., Sanfilippo, F., Andruszkiewicz, P., & Zawadka, M. (2025) · Anaesthesiology Intensive Therapy · doi:10.5114/ait/208895 · Cited by 6
“The most common side effects of this class of drugs are related to the gastrointestinal system: nausea, heartburn, vomiting, dyspepsia, diarrhoea, obstruction, and abdominal pain [26].”
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
Lahoud, C., Kreidieh, M., & Deeb, L. S. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01961-w · Cited by 3
“Nevertheless, GLP-1 RAs have gastrointestinal adverse effects such as abdominal pain, constipation, diarrhea, nausea, and vomiting [7].”
Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Frazier, R., & Hasler, W. L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2579117 · Cited by 4
“In the retrospective NIH cross-sectional analysis of 10,328 adults, abdominal pain, bowel disturbances, and nausea and vomiting were more prevalent on liraglutide than semaglutide or exenatide [37].”
InfluentialGao, W., Cai, X., Wang, X. D., & Li, P. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580095 · Cited by 3
“29 32 Regarding vomiting, our meta-analysis revealed a trend toward a higher incidence in the GLP-1 RAs group compared with controls.”
Prevalence of Pre‐Clinical Obesity Among US Adults Receiving Medical and Surgical Obesity Treatment
Samuels, J. M., Holler, E., Spann, M. D., Northup, C. J., & Yuce, T. K. (2026) · Obesity · doi:10.1002/oby.70171 · Cited by 3
“Previous studies reported that increasing age and male sex are associated with greater odds of gastrointestinal adverse events, both minor and major, following GLP-1 RA use, as was the presence of comorbidities such as chronic kidney disease and heart failure [17, 18].”
Michalak, W., Bøg, M., Bendixen, T., Chowdhury, R., Cowley, P., Laugesen, C., Rathor, N., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70919 · Cited by 4
“…a significantly lower risk of treatment discontinuation due to any AE and due to GI AEs compared with orforglip-ron 36 mg. Clinically, this finding is pertinent because GI AEs are common with GLP-1 RAs [13, 42], and in both OASIS 4 and ATTAIN-1, these were the most frequently reported AEs [16, 19].”
Gmehlin, C. G., Nemet, M., Rizwan, Z. M., Ahmad, S. R., Gajic, O., & Tekin, A. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001263 · Cited by 6
Coutinho, S., Varghese, C., Buenz, E. J., Calder, S. S., Gharibans, A. A., O’Grady, G., Daker, C., & Andrews, C. N. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.07.027 · Cited by 2
Boudreau, B., & Watson, N. C. (2025) · Cureus · doi:10.7759/cureus.95986 · Cited by 2
“Along with their beneficial effects on glycemic control and metabolic disease, GLP-1 RAs have been shown to cause significant gastrointestinal (GI) side effects, with the most common symptoms being abdominal pain, constipation, diarrhea, and nausea/vomiting [4].”
Dietary Modulation and Clinical Outcomes During GLP-1 Receptor Agonist Therapy. A Literature Review
Rychlica, K., Gawin, K., Zawiślak, W., Ignasiak, A., Cisowski, M., Dąbrowska, M., Cholewińska-Rychlica, J., Madura, P., & Mrozik-Gałecka, D. (2026) · Quality in Sport · doi:10.12775/qs.2026.49.67649 · Cited by 2
Prevention of Weight Regain After GLP1RA Cessation With Oral TIX100
JO, S., Chen, J., JING, G., Xu, G., Li, P., & Shalev, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70633 · Cited by 2
Tobaiqy, M. A., Alqutub, S. T., Alzahrani, M. A., Alazwari, R. H., & Asiri, F. A. (2026) · Saudi Medical Journal · doi:10.15537/1658-3175.8842 · Cited by 2
“Transient adverse effects may be interpreted as major safety concerns without adequate anticipatory guidance, contributing to premature discontinuation [17, 25, 26].”
Proença, C., Lobo, M. G., Rufino, A. T., de Oliveira, J. M. P. F., Freitas, M., Trepiana, J., Portillo, M. P., Carvalho, F. D., & Fernandes, E. G. R. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10075-z · Cited by 2
Rezaeianzadeh, R., & Sadatsafavi, M. (2024) · Thorax · doi:10.1136/thorax-2024-222540 · Cited by 2
Garg, S., Qapaja, T., Hamid, O., Kaya, G., Abdel-Razeq, R. H., Alayan, D., Abu-Rumaileh, M. A., Lembo, A. J., & Nissen, S. E. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100736 · Cited by 1
Refaeli, R., Green, G., Boaz, M., Dotan, I., Raziel, A., Peffer-Gik, T., Buch, A., & Dagan, S. S. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01887-2 · Cited by 2
Choo, Y. N., Narayanan, R., & Subramaniyan, V. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107553 · Cited by 2
Wen, J., Puglisi, J. L., & Frezza, E. E. (2025) · Cureus · doi:10.7759/cureus.96771 · Cited by 2
“[13].”
InfluentialSenthilkumar, A., Hays, H. L., Kistamgari, S., Rine, N. I., Rhodes, A. L., Gaw, C. E., & Smith, G. A. (2026) · Journal of Medical Toxicology · doi:10.1007/s13181-026-01128-6 · Cited by 1
“Consistent with prior clinical trial data, the most common related clinical effects in our study were gastrointestinal, including nausea, vomiting, abdominal pain, and diarrhea [34, 47–49].”
Abraham, R., Foong, D., Piya, M. K., Grudzinskas, K., & Ho, V. (2026) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm25156 · Cited by 1
Boerhaave’s syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report
Aubrey, J. M., Benner, C., & Lam, G. T. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04214-6 · Cited by 1
“Gastrointestinal adverse effects, particularly nausea, vomiting, abdominal discomfort, diarrhea, and delayed gastric emptying are frequently reported [2].”
Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension
Amdahl, M. B., Bharadiya, V., Obritsch, B., Obadi, O., Wong, M. Y., Rode, M. M., Colletti, J., Puentes, G. A. C., Chen, J., & Dahiya, G. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.110452 · Cited by 1
Wang, J., Wei, W., Yao, P., Li, J., & Li, H. (2025) · Medicine · doi:10.1097/md.0000000000042408 · Cited by 1
“[14] In this case, the patient reported abdominal pain on the 2nd day of liraglutide use.”
Kalgaonkar, S., Bolster, D. R., Bolster, D., Melo, L., Treadway, S., Chinta, S., Bloor, S., Black, H., Coy, E., Hobson, A., et al. (2025) · Bioactive Compounds in Health and Disease · doi:10.31989/bchd.v8i6.1655 · Cited by 1
Sitompul, V. G., & Nugrahaningsih, W. H. (2025) · Journal of Science and Technology Research for Pharmacy · doi:10.15294/jstrp.v5i1.27250
“However, long-term use of these drugs is not free from side effects such as hypoglycemia, gastrointestinal disorders, and increased risk of liver and kidney toxicity (Nakhleh & Shehadeh, 2021; Aldhaleei et al ., 2024; Yao et al ., 2024).”
Playter, K. P., Chen, Y.-H., Grant, A. R., Chen, Y., Travers, H. I., Hollenbeck, B. L., Nin, D. Z., Niu, R., Talmo, C. T., Chang, D., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7490872/v1
ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH
Sapeda, N., Lusarczyk, W., Truszyńska-Zawisza, A., Gorczyca, K., Młocek, A., Romanowska, Z., & Białas, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4111
Real-world insights into antiobesity medications in an online patient community: a feasibility studyPreprint
Kalich, B. A., Cruz, M., Shaw, S. Y., Cordova, J. M., Ke, H., Mina, M. J., Chen, B., & Burton, P. (2026) · medRxiv · doi:10.64898/2026.01.26.26344623
Chung, K. H., & Kim, J. (2026) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2026.31.1.1
Az endoszkópos vizsgálatok sajátosságai inkretinkezelés alatt cukorbetegeknél és obesitas esetén
Buzás, G. M. (2026) · Central European Journal of Gastroenterology and Hepatology · doi:10.33570/ceujgh.12.1.16
Lai, J. C. (2026) · IIC - International Review of Intellectual Property and Competition Law · doi:10.1007/s40319-026-01692-y
Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis
Kamel‐Abusalha, L. B., Afifi, A. M., Dawoud, A., Hayath, Z., Bouso, M. F., Aguillon, A., & Assaly, R. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01929-0
“Unmea - sured confounding variables such as socioeconomic status, found increased gastrointestinal (GI) adverse events in GLP-1RA users, which could contribute to nocturnal reflux and sleep disruption [17].”
Ding, X., Vadini, V., Kim, C., Bu, F., Chen, H. Y., Chai, Y., Duarte‐Salles, T., Hsu, J. C., Khera, R., Lau, W. C. Y., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350252
The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review
Hatzis, G., McKennitt, A., Gerber, B. S., Quinn, R., & Lee, J. A. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag044
Parekh, R. S., Inban, P., Thai, A., Agrawal, A., Kudaiarov, D., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102150
Chen, Q., Chen, T., Lin, W., & Chen, X. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351059
“(4) Adverse event costs—Excluded because GLP-1 RA-related gastrointestinal symptoms are self-limited (medical intervention rate:1.2%−3.5% [21]), and discontinuation rates were below significance thresholds in the SUSTAIN-7 trial [22] ( dulaglutide 2.4%, semaglutide 3.1%).”
InfluentialAbegaz, T. M., Frietze, G. A., & Das, A. B. (2026) · AI in Medicine · doi:10.3390/aimed1030019
“Although hemorrhoids are not traditionally considered in pharmacovigilance studies of GLP-1 RAs, their prominence in the SHAP analysis may reflect underlying alterations in bowel habits, particularly constipation and straining, which are well-documented adverse effects of GLP-1 RA therapy [27].”
Self-citationShegena, E. A., Kiflu, M., Ahmed, M. B., Bhagavathula, A. S., & Abegaz, T. M. (2026) · Obesity Reviews · doi:10.1111/obr.70200
Self-citationGlucagon‐like Peptide‐1 Receptor Agonists and the Perioperative Patient
Fischer, L. (2026) · AORN Journal · doi:10.1002/aorn.70127
EFETIVIDADE E SEGURANÇA DA SEMAGLUTIDA PARA FINS DE EMAGRECIMENTO: UMA REVISÃO INTEGRATIVA
da Silva, B. O., Bastos, E. M. C., Lira, S. M., Oliveira, J. V. S., & da Silva, D. M. A. (2026) · Revista Interfaces Saúde Humanas e Tecnologia · doi:10.16891/2317-434x.v14.e1.a2026.id3131
An Updated Review of Glucagon-Like Peptide-1 Receptor Agonists
Coleman, J. R., Levine, A., & Weigel, W. (2026) · Advances in Anesthesia · doi:10.1016/j.aan.2026.04.001
Ammendolia, I., Mondello, C., Esposito, E., Calapai, G., Currò, M., Midiri, P., Firenzuoli, B., Noto, A., Cancellieri, A., Cardia, L., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05813-9
Satoh, H., Akiba, Y., & Kaunitz, J. D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105024
Women’s Kidney Health in Focus: A Scientific Statement From the American Heart Association
Gohar, E. Y., Oh, E. S., Ahmed, S. B., Karumanchi, S. A., Mathew, R. O., Norouzi, S., Piccoli, G. B., Reckelhoff, J. F., Vinson, A., Cardozo, L. L. Y., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001471
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
“53 A comparison of RCT ‐ derived incidence ranges with NIH All of Us real ‐ world data across all major GI adverse events is provided in Table 4.”
Fisch, S., Neugut, E. J., Cornet, N., Quigee, D., Neugut, A. I., & Freedberg, D. E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1936967 · Cited by 1
Cisneros, J. Z., Camilleri, M., & Grover, M. (2026) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/agl.v56i3.690
Insights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity
Elashi, A. A., Hedaya, L., Maggio, V., Naja, K., Rizzo, M., & Elrayess, M. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1812193
“Population-based data from the “All of Us” Research Program cohort (Aldhaleei et al., 2024) emphasized that demographic factors can modulate adverse event risk.”
Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists
Cisneros, J. Z., Lupianez‐Merly, C., Dilmaghani, S., Lennon, R. J., Then, S., Fiero, P., Blundo, R., Farrugia, G., Camilleri, M., & Grover, M. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70458
“Real-world studies document even higher rates, with one reporting abdominal pain in 57.6% of GLP-1RA users [7].”
InfluentialSAGES surgical management of gastroparesis: systematic review and expert consensus
Calabrese, E., Shehata, D. G., Kumar, S., Marom, G. A., Chan, C., Chandrasekar, N., Galvani, C. A., Kurian, M. S., Vierra, M. A., Akram, I., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13411-2
Blázquez‐Bermejo, Z., Enríquez-Vázquez, D., García‐Romero, E., Mitroi, C. D., Severo, A., Ruiz, I. M. E., Castel, M. A., Solé, J. M., Marco, M. D. V. G., Garrido, I. P., et al. (2026) · Transplantation · doi:10.1097/tp.0000000000005945
Correia, K. M., & Belfort, M. G. S. (2026) · Revista Tópicos. · doi:10.70773/revistatopicos/793411916
Rolak, S. C., Lunsford, T. N., Frazier, R., Harris, L. A., Yang, M., & Hasler, W. L. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70448
Metadata
- Authors
- Aldhaleei, W. A., Abegaz, T. M., & Bhagavathula, A. S.
- Affiliations
- Mayo Clinic (US)
- Florida Agricultural and Mechanical University (US)
- North Dakota State University (US)
- Corresponding author
- Bhagavathula, Akshaya Srikanth
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-02-02
- Volume
- 17
- Issue
- 2
- Pages
- 199
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC10891568
- OpenAlex
- W4391485990
- Cited by
- 80
- References
- 27
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 12
- FWCI
- 26.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- North Dakota State University—RCA Research Support (000365)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, semaglutide, dulaglutide, liraglutide, exenatide, abdominal pain, constipation, diarrhea, nausea and vomiting, gastroparesis, pancreatitis, diabetes mellitus, obesity, drug safety comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

